EGFRgene mutations in patients with adenosquamous lung carcinoma

Abstract

EGFR gene mutations in ADSQ carcinoma patients may be more common than previously thought. EGFR mutation testing is appropriate in ADSQ-bearing patients, in which response for molecular-based therapy is predictable.

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma

“…The observed prevalence (21.5%) of EGFR mutations in patients with ASC was consistent with that reported in previous studies (13–44%, Table S2) . We and others found that EGFR ‐mutated cells were distributed in both AC and SCC components of ASC specimens.…”

“…The observed prevalence (21.5%) of EGFR mutations in patients with ASC was consistent with that reported in previous studies (13-44%, Table S2). [5][6][7][8][9][10][11][12][13] We and others found that EGFR-mutated cells were distributed in both AC and SCC components of ASC specimens. In a case report and series analyses, patients with EGFR mutations in ASC specimens responded to EGFR-TKI therapy with an overall response rate of 88%.…”

“…In lung SCCs, amplification of the gene encoding fibroblast growth factor receptor-1 (FGFR1) has been reported as a target for molecular therapy. Although there have been few large-scale studies of driver gene alterations in ASC as represented by EGFR mutations, the prevalence of EGFR and KRAS mutations in ASC has been reported to be 13-44% and 4-13%, [5][6][7][8][9][10][11][12][13] respectively. There have been only few reports of ALK gene rearrangement 7,14,15 and two cases of ROS1 gene rearrangement in ASC.…”

Detection of Common and Less Frequent <b><i>EGFR</i></b> Mutations in Cytological Samples of Lung Cancer

“…These data might not have been adequately discussed due to the limited series as well as the possibility of taking adenosquamous carcinoma samples lacking the adenocarcinoma component as causes of bias. Few recent papers deemed the possibility that EGFR mutations are more common than expected in adenosquamous carcinoma [32]. …”

Epidermal Growth Factor Receptor Activating Mutations in Squamous Histology of Lung Cancer Patients of Southern Bulgaria

“…This is perhaps the reason why the mutations found in squamous cell carcinomas are far more frequent than those reported by other authors whose studies have been conducted on an adequate number of cases. 10,11,19 The considerable discrepancy in the reported data could be due to differences in the methodology of performing the mutation analysis, but could be also a result of genetic differences between eastern patient populations and other populations. 7 Such ethnic diversity can be found, to a certain extent, in Southern Bulgaria, which makes it necessary to compare these data with data from other regions of the country.…”